MedTrace Logo

Cryoablation+Ipilimumab+Nivolumab in Melanoma

NCT05779423 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2026-05-19

No results posted yet for this study

Summary

The aim of this study is to find out whether the combination of two approved drugs, ipilimumab and nivolumab, in combination with cryoablation are safe and effective for participants who have an unresectable melanoma that is resistant, or is growing, after receiving immunotherapy with a PD-1 inhibitor.

The names of the study interventions involved in this study are:

* Cryoablation (an interventional radiology procedure that freezes part of a tumor)
* Ipilimumab (an immunotherapy)
* Nivolumab (an immunotherapy)

Conditions

Interventions

DRUG

Nivolumab

Monoclonal antibody administered through intravenous infusion

PROCEDURE

Cryoablation

Procedure of freezing a tumor performed via CT-guidance by interventional radiologist.

DRUG

Ipilimumab

Monoclonal antibody administered through intravenous infusion

Sponsors & Collaborators

Principal Investigators

  • Meghan J Mooradian, MD · Massachusetts General Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-09-23
Primary Completion
2028-01-01
Completion
2028-01-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05779423 on ClinicalTrials.gov